Public Profile

DAIICHI SANKYO GROUP

DAIICHI SANKYO GROUP, a prominent player in the global pharmaceutical industry, is headquartered in Japan (JP) and operates extensively across Asia, Europe, and the Americas. Founded in 2005 through the merger of Daiichi Pharmaceutical and Sankyo Company, Limited, the group has since achieved significant milestones, including advancements in oncology and cardiovascular treatments. Specialising in innovative medicines, DAIICHI SANKYO is renowned for its unique drug development capabilities, particularly in targeted therapies and biologics. The company’s commitment to research and development has positioned it as a leader in the pharmaceutical market, with notable achievements such as the successful launch of several blockbuster drugs. With a strong focus on improving patient outcomes, DAIICHI SANKYO continues to make strides in the healthcare sector, solidifying its reputation as a trusted name in pharmaceuticals.

DitchCarbon Score

How does DAIICHI SANKYO GROUP's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.

58

Industry Average

Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.

30

Industry Benchmark

DAIICHI SANKYO GROUP's score of 58 is higher than 94% of the industry. This can give you a sense of how well the company is doing compared to its peers.

94%

Let us know if this data was useful to you

DAIICHI SANKYO GROUP's reported carbon emissions

In 2023, DAIICHI SANKYO GROUP reported total greenhouse gas emissions of approximately 4,430,241,000 kg CO2e, with emissions distributed across various scopes: 85,245,000 kg CO2e (Scope 1), 23,994,000 kg CO2e (Scope 2), and 4,430,241,000 kg CO2e (Scope 3). This marked a significant increase in Scope 3 emissions compared to previous years, highlighting the importance of addressing upstream supply chain impacts. The company has set ambitious climate commitments, aiming for net-zero greenhouse gas emissions by FY2050. To achieve this, DAIICHI SANKYO has established several near-term targets, including a commitment to reduce absolute Scope 1 and Scope 2 emissions by 63% by FY2030 from a FY2015 baseline. Additionally, they plan to increase their sourcing of renewable electricity from 4% in FY2015 to 100% by FY2030. Furthermore, DAIICHI SANKYO aims for 70.6% of its suppliers, based on emissions, to have science-based targets by FY2025. In 2021, the company reported Scope 1 emissions of approximately 88,249,000 kg CO2e and Scope 2 emissions of about 103,150,000 kg CO2e, with Scope 3 emissions at approximately 513,874,000 kg CO2e. By 2022, Scope 1 emissions decreased to about 86,006,000 kg CO2e, while Scope 2 emissions significantly dropped to approximately 23,729,000 kg CO2e, indicating progress in reducing direct emissions. DAIICHI SANKYO's commitment to sustainability is further underscored by its adherence to the Science Based Targets initiative (SBTi), which validates its targets as consistent with the reductions required to limit global warming to well below 2°C. The company is actively working to enhance its environmental performance and reduce its carbon footprint across all operations.

Unlock detailed emissions data

Access structured emissions data, company-specific emission factors, and source documents

2020202120222023
Scope 1
86,785,000
00,000,000
00,000,000
00,000,000
Scope 2
96,080,000
000,000,000
00,000,000
00,000,000
Scope 3
609,954,000
000,000,000
0,000,000,000
0,000,000,000

Industry emissions intensity

Very low
Low
Medium
High
Very high
Some industries are more carbon intensive than others. DAIICHI SANKYO GROUP's primary industry is Pharmaceutical Preparation Manufacturing, which is very low in terms of carbon intensity compared to other industries.

Location emissions intensity

Very low
Low
Medium
High
Very high
The carbon intensity of the energy grid powering a company's primary operations has a strong influence on its overall carbon footprint. This request for DAIICHI SANKYO GROUP is in JP, which has a low grid carbon intensity relative to other regions.

Reduction initiatives & disclosure networks

Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.

DAIICHI SANKYO GROUP is participating in some of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.

Science Based Targets Initiative
Carbon Disclosure Project
The Climate Pledge
UN Global Compact
RE 100
Climate Action 100
Race To Net Zero
Reduction Actions

Similar Organizations

TG Therapeutics, Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sandoz International GmbH

DE
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Sanofi Pasteur Inc.

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Astellas

JP
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Allergan

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Celgene Corporation

US
Pharmaceutical Preparation Manufacturing
Updated 3 days ago

Where does DitchCarbon data come from?

Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers